Holen Sie sich die Stockscreener-App
4.95
0.20%
-0.010
Handel nachbörslich:
4.86
-0.09
-1.82%
Schlusskurs vom Vortag:
$4.96
Offen:
$4.95
24-Stunden-Volumen:
30,275
Relative Volume:
0.45
Marktkapitalisierung:
$42.63M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-34.77M
KGV:
-1.4956
EPS:
-3.3097
Netto-Cashflow:
$-29.79M
1W Leistung:
+4.32%
1M Leistung:
-13.16%
6M Leistung:
-57.68%
1J Leistung:
-60.32%
1-Tages-Spanne:
$4.8631
$5.055
1-Wochen-Bereich:
$4.6601
$5.10
52-Wochen-Spanne:
$3.76
$19.35
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Firmenname
Atossa Therapeutics Inc
Sektor
Branche
Telefon
206.588.0256
Adresse
1448 NW MARKET STREET, SEATTLE, WA
Compare ATOS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
4.95 | 42.71M | 0 | -34.77M | -29.79M | -3.3097 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-01-26 | Eingeleitet | Maxim Group | Buy |
Atossa Therapeutics Inc Aktie (ATOS) Neueste Nachrichten
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
ATOS News | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill
ATOS Stock Price, Quote & Chart | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill
Atossa Therapeutics advances research on Z-endoxifen for Duchenne muscular dystrophy - Traders Union
Atossa's New Research Findings on DMD - Intellectia AI
New review links (Z)-endoxifen to key Duchenne muscle pathways - Stock Titan
Atossa Therapeutics, Inc. (ATOS) Latest Stock News & Headlines - Yahoo Finance
Atossa Therapeutics (ATOS) price target decreased by 47.43% to 23.46 - MSN
ATOS Should I Buy - Intellectia AI
Atossa Therapeutics (ATOS) director granted 10,000 RSUs vesting after 2026 - Stock Titan
ATOS (ATOS) director Stephen Galli receives 10,000 RSU equity grant - Stock Titan
Atossa Therapeutics (ATOS) director granted 10,000 RSUs in stock award - Stock Titan
Atossa (NASDAQ: ATOS) director awarded 10,000 RSUs in stock grant - Stock Titan
Atossa Therapeutics (ATOS) director granted 10,000-share RSU award - Stock Titan
Atossa Therapeutics (NASDAQ: ATOS) director receives 10,000 RSUs award - Stock Titan
Atossa Therapeutics brings experts together to examine endocrine therapy backbone potential - Traders Union
Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer - BioSpace
Atossa Therapeutics, Inc. (ATOS) latest stock news and headlines - Yahoo Finance Singapore
Atossa Therapeutics, Inc.Common Stock (NQ: ATOS - FinancialContent
ATOSSA THERAPEUTICS, INC. secures FDA rare pediatric disease status for Z-endoxifen in McCune-Albright syndrome - Traders Union
Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $20 - Moomoo
H.C. Wainwright Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Atossa Therapeutics (ATOS) Progresses in (Z)-endoxifen Developme - GuruFocus
Atossa Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Atossa Therapeutics Reports Q1 2026 Financial Results (ATOS) - GuruFocus
FDA designations and clinical progress drive Atossa Therapeutics Q1 2026 financial report - Traders Union
Atossa Therapeutics Inc expected to post a loss of $1.03 a shareEarnings Preview - TradingView
Atossa Therapeutics Q1 net loss widens on higher legal and R&D expenses - TradingView
Atossa Therapeutics Shareholders Approve Proposals at 2026 Meeting - TipRanks
Atossa Therapeutics (ATOS) deepens Q1 2026 loss while expanding (Z)-endoxifen pipeline - Stock Titan
Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update - PR Newswire
Atossa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] ATOSSA THERAPEUTICS, INC. Quarterly Earnings Report - Stock Titan
Atossa Therapeutics (NASDAQ: ATOS) wins OK for potential reverse stock split - Stock Titan
Atossa Therapeutics (ATOS) Reports Positive Data from KARISMA En - GuruFocus
MSN Money - MSN
Gross margin % of Atossa Therapeutics, Inc. – DUS:YAG - TradingView
Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women - StreetInsider
Number of shareholders of Atossa Therapeutics, Inc. – NASDAQ:ATOS - TradingView
Atossa Therapeutics, Inc. Balance Sheet – DUS:YAG - TradingView
Atossa Therapeutics, Inc. Cash Flow – DUS:YAG - TradingView
Number of shareholders of Atossa Therapeutics, Inc. – DUS:YAG - TradingView
Atossa Therapeutics, Inc. Revenue Breakdown – DUS:YAG - TradingView
Atossa reports breast density reduction in endoxifen trial - Investing.com UK
Atossa Therapeutics posts trial data showing reduced breast density in premenopausal women - Traders Union
Atossa reports breast density reduction in endoxifen trial By Investing.com - Investing.com India
ATOS Stock Jumps 8% Today – An FDA Designation Draws Investor Cheer For Atossa Therapeutics - Stocktwits
Atossa Genetics stock surges after FDA rare disease designation By Investing.com - Investing.com South Africa
Finanzdaten der Atossa Therapeutics Inc-Aktie (ATOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):